stockrowWhitehawk Therapeutics, Inc.
WHWKWhitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024.
- Revenue
- +33.5%
- EPS
- +73.7%
- Free cash flow
- +72.6%
Quarter to June 2026, against a year earlier
Follow WHWK
Alert me
Whitehawk Therapeutics, Inc. (WHWK) EV/Sales
As of 6 November 2026, Whitehawk Therapeutics, Inc. (WHWK) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from −6.2× (April 2025) to 107× (January 2022); the current reading is higher than 71% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (87.68%) |
| FY2024 | 1.5× | — |
| FY2023 | −2.2× | — |
| FY2022 | 6.9× | (92.81%) |
| FY2021 | 96.6× | 4,041.77% |
| FY2020 | 2.3× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | −5.7× | — |
| Dec 2024 | 1.5× | — |
| Sep 2024 | −0.2× | — |
| Jun 2024 | −1.6× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −26.9× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −2.3× |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IVVD Invivyd, Inc. compare | 0.3× |
| CGEN Compugen Ltd. compare | 0.8× |
| WHWK Whitehawk Therapeutics, Inc. | 2.5× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| MDWD MediWound Ltd. compare | 12.6× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)